The FDA has approved Soliris the first-ever treatment for children with generalized myasthenia gravis gMG offering new hope in pediatric neuromuscular care Learn more!

New data from the phase 3 MINT trial in adults living with autoimmune disorder generalised myasthenia gravis (gMG) – which ...

Oppenheimer reiterates a Perform rating on Cartesian Therapeutics (RNAC) without a price target following the company’s Q4 report. The company’s Phase 3 trial in myasthenia gravis remains on track to ...

US biotech major Amgen has announced new data from the Phase III MINT trial of Uplizna (inebilizumab-cdon) in adults living with generalized myasthenia gravis (gMG).

H.C. Wainwright lowered the firm’s price target on Cartesian Therapeutics (RNAC) to $40 from $45 and keeps a Buy rating on the shares. The firm ...

An obituary for a 77-year-old woman has caught the attention of social media, with one declaring, “Who is this icon?” ...

Legendary former Republic of Ireland star appears on RTE's The Late Late Show this evening as we celebrate the legends of ...

Guggenheim reiterated their buy rating on shares of Dianthus Therapeutics (NASDAQ:DNTH – Free Report) in a research note released on Wednesday,Benzinga reports. They currently have a $84.00 price ...

Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at Needham & Company LLC in a research report issued on Thursday,Benzinga reports.

Alnylam Pharmaceuticals ALNY focuses on developing novel therapeutics based on RNAi technology. The company’s pipeline of ...

According to Prof Phil Banfield, chair of BMA council, it had become clear that the centre "no longer has a grip on the ...

Aristotle Onassis' death, the Greek tycoon's legend lives on—wealth, shipping empire, and legacy endure, from Smyrna to ...